Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Viatris

Is Viatris Stock Underperforming the Nasdaq?

Viatris has lagged the broader Nasdaq Composite over the past year, and Wall Street sentiment toward the stock remains guarded.

Barchart

Viatris Stock: Analyst Estimates & Ratings

Viatris has considerably underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Barchart

What to Expect From Viatris' Next Quarterly Earnings Report

Viatris is all set to release its fiscal second-quarter earnings next month, and analysts project a double-digit earnings drop.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

As the pharmaceutical industry increasingly focuses on developing targeted treatments for niche conditions, Viatris Inc. (NASDAQ:VTRS) on Friday announced topline data from a Phase 3 study evaluating the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis.

Benzinga

Is Viatris Stock Underperforming the S&P 500?

Viatris has significantly underperformed the S&P 500 over the past year, and analysts remain cautious about the stock’s prospects.

Barchart

Do Wall Street Analysts Like Viatris Stock?

Viatris has underperformed the broader market over the past year, and analysts remain skeptical of the stock’s future potential.

Barchart

What to Expect From Viatris' Q1 2025 Earnings Report

Viatris is scheduled to report its first-quarter results next month, and analysts expect a double-digit earnings drop.

Barchart

Read news from The Economist, FT, and more,
with one subscription

How Is Viatris’ Stock Performance Compared to Other Biotech Stocks?

Over the past six months, Viatris has lagged behind its biotech peers, and Wall Street analysts continue to exercise caution regarding the stock's future outlook.

Barchart

Viatris Stock Outlook: Is Wall Street Bullish or Bearish?

As Viatris has trailed the broader market over the past year, analysts are skeptical about its future outlook.

Barchart

Here's What to Expect From Viatris' Next Earnings Report

Viatris is scheduled to release its fourth-quarter earnings next month, and analysts anticipate a profit dip.

Barchart

Viatris Stock: Is VTRS Outperforming the Healthcare Sector?

Despite Viatris’ recent outperformance relative to its broader sector, Wall Street analysts remain cautious about the stock’s prospects.

Barchart

More ‘discreet’ Viagra-type drug could soon be available in Britain

US company Viatris has applied for a UK trademark for wafer-like film that dissolves in the mouth

The Guardian - UK

2 Generic Drug Stocks Ready to Surge in 2025

Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.

MarketBeat

Are Wall Street Analysts Predicting Viatris Stock Will Climb or Sink?

Due to Viatris’ underperformance relative to the broader S&P 500 Index over the past year, Wall Street analysts remain cautious about the stock’s prospects.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Earnings Preview: What to Expect From Viatris' Report

Viatris is all set to announce its third-quarter results next month, with analysts predicting a double-digit decline in the company's earnings.

Barchart

How To Spot Good Value Stocks In A Sea Of Noise

Explore why traditional value investing often falls short and how catalysts can transform undervalued stocks into lucrative investments.

Barchart

Is Viatris Stock Underperforming the Dow?

Viatris has underperformed the Dow Jones Industrial Average over the past year, and analysts remain cautious about the stock’s prospects.

Barchart

Is Wall Street Bullish or Bearish on Viatris' Stock?

Viatris has underperformed the broader market over the past year, and Wall Street analysts are cautious about the stock’s prospects.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Viatris Quarterly Earnings Preview: What You Need to Know

Viatris is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip.

Barchart

Stocks Close Higher on Fed Rate Cut Optimism

The S&P 500 Index ($SPX ) (SPY ) Thursday closed up +0.51%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.85%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.16%. US stock indexes on Thursday settled higher, with the S&P 500 climbing to a...

Barchart

Stocks Rise on Fed Rate Cut Hopes

The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.32%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.13%. US stock indexes this morning are moderately higher, with the S&P 500 climbing...

Barchart

Stocks Mixed as Weekly Jobless Claims Climb to an 8-1/2 Month High

The S&P 500 Index ($SPX ) (SPY ) this morning is down -0.04%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.27%. US stock indexes this morning are mixed, with the Dow Jones Industrials posing...

StockNews.com

3 Pharma Stocks Outperforming the Competition

The growing demand for innovative drugs, the use of advanced technologies, and growing global healthcare needs boost the pharmaceutical industry’s long-term growth prospects. Therefore, fundamentally strong pharma stocks Viatris (VTRS), Wave Life Sciences (WVE), and MEI Pharma (MEIP) might be ideal additions to your portfolio. Read on.

The Independent UK

Stock market today: Asia mixed after Wall St rallies ahead of US inflation update

Asian stocks are mixed after Wall Street rallied and Japanese wages rose ahead of a U.S. inflation update that might influence Federal Reserve plans for possible interest rate hikes

Birmingham Post

Shield Therapeutics hails US market progress and mulls stateside listing

The Gateshead company said additional losses were to be expected as it carries out a plan to target US iron deficiency treatment demand

1 2

People

Daly

91 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.